Citigroup’s Bionano Genomics BNGO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1 Buy
+1
New +$1 ﹤0.01% 5851
2025
Q1
Sell
-117
Closed -$2.03K 5603
2024
Q4
$2.03K Hold
117
﹤0.01% 5546
2024
Q3
$3.19K Hold
117
﹤0.01% 5379
2024
Q2
$4.76K Hold
117
﹤0.01% 5262
2024
Q1
$7.8K Hold
117
﹤0.01% 5255
2023
Q4
$13.3K Sell
117
-75
-39% -$7.83K ﹤0.01% 5123
2023
Q3
$34.9K Sell
192
-14
-7% -$3.67K ﹤0.01% 4245
2023
Q2
$75.3K Buy
206
+42
+26% +$19K ﹤0.01% 4378
2023
Q1
$109K Sell
164
-13
-7% -$11.5K ﹤0.01% 3978
2022
Q4
$155K Sell
177
-144
-45% -$181K ﹤0.01% 3844
2022
Q3
$352K Sell
321
-113
-26% -$149K ﹤0.01% 3480
2022
Q2
$359K Sell
434
-157
-27% -$162K ﹤0.01% 3467
2022
Q1
$915K Sell
591
-115
-16% -$155K ﹤0.01% 3056
2021
Q4
$1.27M Buy
706
+59
+9% +$158K ﹤0.01% 3003
2021
Q3
$2.13M Hold
647
﹤0.01% 2495
2021
Q2
$2.85M Buy
647
+160
+33% +$632K ﹤0.01% 2384
2021
Q1
$2.36M Buy
+487
New +$2.75M ﹤0.01% 2389

Other funds holding BNGO

Citigroup's BNGO Position: Q1 2026 in Review

Citigroup opened a new position in Bionano Genomics (BNGO) in Q1 2026: 1 share worth $1. The stake represents ﹤0.01% of the portfolio and ranks #5851 among its holdings. This is a return to the name: Citigroup previously reported a position in BNGO as recently as Q4 2024.

Citigroup first reported a position in BNGO in Q1 2021 and has held it in 17 quarters since. The position peaked at $2.85M in Q2 2021. 32 funds tracked by Wall St. Rank hold BNGO as of Q1 2026.

  • Citigroup held 1 share of Bionano Genomics worth $1 as of Q1 2026.
  • Bionano Genomics was a new Citigroup position in Q1 2026.
  • Bionano Genomics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5851 holding.
  • Citigroup first reported a position in Bionano Genomics in Q1 2021 and has held it in 17 quarters since.
  • Citigroup's Bionano Genomics position peaked at $2.85M in Q2 2021.
  • 32 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.